Dr Thomas Buttgereit is joined by Dr Carolina Vera to discuss the use of attenuated androgens in the treatment of hereditary angioedema and their associated risks and side effects. Both exerts delve into the safety, ethical considerations and alternative treatment options to using androgens for the treatment of hereditary angioedema. Dr Vera concludes the discussion with an in-depth explanation of the SHAERPA project, focusing on the discontinuation of androgen use in individuals with angioedema, and the benefits this project can have in providing guidance on alternative medications.
Listen on SPOTIFY and APPLE PODCASTS
Do you have suggestions for future episodes? Please provide feedback and offer your suggestions for future topics and expert selection here.
For more information about the GA2LEN ACARE network and its activities please visit https://acare-network.com/. Additional resources relating to the topics discussed in this episode can be found here: The international WAO/EAACI guideline for the management of hereditary angioedema—The 2021 revision and update, Attenuated androgen discontinuation in patients with hereditary angioedema: a commented case series and and WAO Guideline for the Management of Hereditary Angioedema.
Read more news from ACARE
- February 23, 2023
In the hereditary disease hereditary angioedema (HAE), swellings occur in one or more parts of the body without a recognisable trigger. Especially if the upper respiratory tract is affected, a [...]
- October 13, 2023
Dr Thomas Buttgereit is joined by Dr Carolina Vera to discuss the use of attenuated androgens in the treatment of hereditary angioedema and their associated risks and side effects. Both [...]
- March 28, 2023
STATE OF THE ART MANAGEMENT OF RECURRENT ANGIOEDEMA AND HANDS ON TRAINING with special focus on Canada and Europe (applied for CME) Click here to register. The overall aim [...]
